postherpetic neuralgia
Conditions
Interventions
Experimental group:electroacupuncture
Sponsors
Beijing Hospital of Traditional Chinese Medicine, Capital Medical University
Eligibility
Sex/Gender
All
Age
50 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age over 50 years. 2. Meet the diagnostic criteria for postherpetic neuralgia in the 2016 Chinese Expert Consensus on the Treatment of Postherpetic Neuralgia by the Consensus Writing Expert Group on the Treatment of Postherpetic Neuralgia. 3. Patients with PHN agree to receive acute analgesics. 4. The average maximum pain level VAS >= 3 points within 1 week of the screening period. 5. Patients themselves signed the informed consent form and voluntarily participated in this trial.
Exclusion criteria
Exclusion criteria: 1. PHN with previous neurolytic block or neurosurgical treatment. 2. severe pain or neurological disorders unrelated to PHN or the presence of skin changes other than PHN that can cause pain. 3. Patients with mood disorders requiring tricyclic antidepressants, and those with mental and intellectual impairment unable to cooperate with questionnaires. 4. Combined with serious primary diseases such as cardiovascular, cerebrovascular, hepatic, renal and hematopoietic system and other organic lesions such as tumors. 5. Pregnant and lactating women, and those who have a request for childbirth in the last six months. 6. Poorly controlled blood sugar, glycosylated hemoglobin >= 8.0% 7. Patients with immunodeficiency diseases such as pernicious anemia, untreated hypothyroidism or history of HIV infection and history of positive hepatitis B antigen or hepatitis C antibody, active tuberculosis, etc. 8. Patients who have received previous acupuncture treatment. 9.Patients belonging to the vulva and brachial plexus region and special types of herpes zoster, where special types include: ocular and ear herpes zoster, herpes zoster with stenosis, herpes zoster without rash, herpes zoster meningitis or encephalitis, herpes zoster invading visceral nerve fibers, disseminated herpes zoster and other (herpes zoster with maculopapular, hemorrhagic, gangrenous and other manifestations) resulting in PHN. 10. Concurrent participation in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VAS responder rate(>=50%); | — |
Secondary
| Measure | Time frame |
|---|---|
| Intensity of acute zoster-associated pain;McGill Pain Questionnaire;BPI-SF;Time to relieving of pain;Average daily sleep interference score;PGIC;hospital anxiety and depression scale;36- item short form health survey; | — |
Countries
China
Contacts
Public ContactBin Li
Beijing Hospital of Traditional Chinese Medicine, Capital Medical University
Outcome results
None listed